List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1141166/publications.pdf Version: 2024-02-01



Мітенрії Нленіпл

#	Article	IF	CITATIONS
1	The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptake. Pharmaceutical Research, 1995, 12, 825-830.	1.7	403
2	Luminescent proteins for high-speed single-cell and whole-body imaging. Nature Communications, 2012, 3, 1262.	5.8	247
3	Disposition characteristics of macromolecules in tumor-bearing mice. Pharmaceutical Research, 1990, 07, 339-346.	1.7	207
4	Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharmaceutical Research, 1996, 13, 820-831.	1.7	205
5	Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. Journal of Controlled Release, 2006, 111, 333-342.	4.8	182
6	Cell-specific delivery of genes with glycosylated carriers. Advanced Drug Delivery Reviews, 2001, 52, 187-196.	6.6	173
7	Disposition and tumor localization of mitomycin C-dextran conjugates in mice. Pharmaceutical Research, 1987, 04, 293-300.	1.7	163
8	Molecular weight-dependent gene transfection activity of unmodified and galactosylated polyethyleneimine on hepatoma cells and mouse liver. Molecular Therapy, 2003, 7, 254-261.	3.7	163
9	Photodynamic and Photothermal Effects of Semiconducting and Metallic-Enriched Single-Walled Carbon Nanotubes. Journal of the American Chemical Society, 2012, 134, 17862-17865.	6.6	163
10	In Silico Approaches for Predicting ADME Properties of Drugs. Drug Metabolism and Pharmacokinetics, 2004, 19, 327-338.	1.1	162
11	Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Advanced Drug Delivery Reviews, 2009, 61, 319-326.	6.6	162
12	Asialoglycoprotein Receptor-Mediated Gene Transfer Using Novel Galactosylated Cationic Liposomes. Biochemical and Biophysical Research Communications, 1998, 252, 78-83.	1.0	161
13	Effect of DNA/liposome mixing ratio on the physicochemical characteristics, cellular uptake and intracellular trafficking of plasmid DNA/cationic liposome complexes and subsequent gene expression. Journal of Controlled Release, 2000, 66, 255-269.	4.8	160
14	In vivo gene delivery to the liver using novel galactosylated cationic liposomes. Pharmaceutical Research, 2000, 17, 306-313.	1.7	155
15	Physicochemical and Pharmacokinetic Characteristics of Plasmici DNA/ Cationic Liposome Complexes. Journal of Pharmaceutical Sciences, 1995, 84, 1267-1271.	1.6	152
16	Targeted delivery of plasmid DNA complexed with galactosylated poly(l-lysine). Journal of Controlled Release, 1998, 53, 301-310.	4.8	141
17	Creation of Pure Nanodrugs and Their Anticancer Properties. Angewandte Chemie - International Edition, 2012, 51, 10315-10318.	7.2	140
18	Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. Journal of Controlled Release, 2008, 125, 121-130.	4.8	137

#	Article	IF	CITATIONS
19	Efficient Gene Transfection by Histidine-Modified Chitosan through Enhancement of Endosomal Escape. Bioconjugate Chemistry, 2010, 21, 1087-1095.	1.8	133
20	Long Circulating Emulsion Carrier Systems for Highly Lipophilic Drugs Biological and Pharmaceutical Bulletin, 1994, 17, 121-125.	0.6	132
21	Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials, 2007, 28, 1434-1442.	5.7	130
22	Effect of particle size and charge on the disposition of lipid carriers after intratumoral injection into tissue-isolated tumors. Pharmaceutical Research, 1998, 15, 128-132.	1.7	125
23	PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. Journal of Controlled Release, 2006, 116, 330-336.	4.8	124
24	Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. Journal of Pharmaceutical Sciences, 2008, 97, 726-745.	1.6	124
25	Extravasation of macromolecules. Advanced Drug Delivery Reviews, 1998, 34, 93-108.	6.6	122
26	Hepatic uptake of polystyrene microspheres in rats: Effect of particle size on intrahepatic distribution. Journal of Controlled Release, 1999, 59, 15-22.	4.8	119
27	Structure–Activity Relationship of 1-Alkyl- or 1 -Alkenylazacycloal kanone Derivatives as Percutaneous Penetration Enhancers. Journal of Pharmaceutical Sciences, 1988, 77, 418-424.	1.6	113
28	Macromolecular drug carrier systems in cancer chemotherapy: macromolecular prodrugs. Critical Reviews in Oncology/Hematology, 1995, 18, 207-231.	2.0	113
29	Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochimica Et Biophysica Acta - General Subjects, 2000, 1524, 258-265.	1.1	113
30	Designing Dendrimers for Drug Delivery and Imaging: Pharmacokinetic Considerations. Pharmaceutical Research, 2011, 28, 1500-1519.	1.7	113
31	Pharmacokinetic considerations for targeted drug delivery. Advanced Drug Delivery Reviews, 2013, 65, 139-147.	6.6	111
32	In Vivo Disposition Characteristics of Plasmid DNA Complexed with Cationic Liposomes. Journal of Drug Targeting, 1995, 3, 149-157.	2.1	108
33	Biodistribution characteristics of amino acid dendrimers and their PEGylated derivatives after intravenous administration. Journal of Controlled Release, 2006, 114, 69-77.	4.8	105
34	Strategies for In Vivo Delivery of siRNAs. BioDrugs, 2010, 24, 195-205.	2.2	105
35	Photothermal ablation of tumor cells using a single-walled carbon nanotube–peptide composite. Journal of Controlled Release, 2014, 173, 59-66.	4.8	104
36	Ultrasound induced cancer immunotherapy. Advanced Drug Delivery Reviews, 2014, 72, 144-153.	6.6	103

#	Article	IF	CITATIONS
37	Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy Biological and Pharmaceutical Bulletin, 2002, 25, 275-283.	0.6	101
38	Nonviral Vectors for In Vivo Gene Delivery: Physicochemical and Pharmacokinetic Considerations. Critical Reviews in Therapeutic Drug Carrier Systems, 1997, 14, 40.	1.2	101
39	Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochemical and Biophysical Research Communications, 2004, 317, 992-999.	1.0	99
40	Photothermic regulation of gene expression triggered by laser-induced carbon nanohorns. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7523-7528.	3.3	96
41	Evaluation of Proinflammatory Cytokine Production Induced by Linear and Branched Polyethylenimine/Plasmid DNA Complexes in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1382-1390.	1.3	95
42	Targeted Delivery Systems of Small Interfering RNA by Systemic Administration. Drug Metabolism and Pharmacokinetics, 2007, 22, 142-151.	1.1	94
43	Factors Affecting Drug and Gene Delivery: Effects of Interaction with Blood Components. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 191-234.	1.2	93
44	Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochemical and Biophysical Research Communications, 1992, 189, 191-196.	1.0	91
45	Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(l-lysine). Biochemical Pharmacology, 1997, 53, 887-895.	2.0	91
46	The role of dioleoylphosphatidylethanolamine (DOPE) in targeted gene delivery with mannosylated cationic liposomes via intravenous route. Journal of Controlled Release, 2005, 108, 484-495.	4.8	90
47	Lipid Carrier Systems for Targeted Drug and Gene Delivery. Chemical and Pharmaceutical Bulletin, 2005, 53, 871-880.	0.6	86
48	Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials, 2007, 28, 3255-3262.	5.7	86
49	Development of an ultrasound-responsive and mannose-modified gene carrier for DNA vaccine therapy. Biomaterials, 2010, 31, 7813-7826.	5.7	85
50	piggyBac Transposon-mediated Long-term Gene Expression in Mice. Molecular Therapy, 2010, 18, 707-714.	3.7	84
51	Effect of Galactose Density on Asialoglycoprotein Receptor-Mediated Uptake of Galactosylated Liposomes. Journal of Pharmaceutical Sciences, 2005, 94, 2266-2275.	1.6	82
52	γ-Polyglutamic acid-coated vectors for effective and safe gene therapy. Journal of Controlled Release, 2010, 142, 404-410.	4.8	81
53	Modeling of Rifampicin-Induced CYP3A4 Activation Dynamics for the Prediction of Clinical Drug-Drug Interactions from In Vitro Data. PLoS ONE, 2013, 8, e70330.	1.1	78
54	Synthesis and pharmacokinetics of a new liver-specific carrier, glycosylated carboxymethyl-dextran, and its application to drug targeting. Pharmaceutical Research, 1993, 10, 1253-1261.	1.7	77

#	Article	IF	CITATIONS
55	Effect of mannose density on mannose receptor-mediated cellular uptake of mannosylated O/W emulsions by macrophages. Journal of Controlled Release, 2006, 114, 193-201.	4.8	77
56	Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells. Journal of Controlled Release, 2007, 118, 262-270.	4.8	77
57	Mechanistic and empirical modeling of skin permeation of drugs. Advanced Drug Delivery Reviews, 2003, 55, 1185-1199.	6.6	74
58	Inhibition of Metastatic Tumor Growth in Mouse Lung by Repeated Administration of Polyethylene Glycol-Conjugated Catalase. Clinical Cancer Research, 2004, 10, 7685-7691.	3.2	72
59	Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice. International Journal of Pharmaceutics, 1992, 85, 75-85.	2.6	70
60	Involvement of Specific Mechanism in Plasmid DNA Uptake by Mouse Peritoneal Macrophages. Biochemical and Biophysical Research Communications, 1998, 245, 729-733.	1.0	70
61	Plasmid DNA activates murine macrophages to induce inflammatory cytokines in a CpG motif-independent manner by complex formation with cationic liposomes. Biochemical and Biophysical Research Communications, 2002, 293, 344-348.	1.0	70
62	Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. Pharmaceutical Research, 1991, 08, 437-444.	1.7	69
63	Inhibition of experimental pulmonary metastasis by controlling biodistribution of catalase in mice. International Journal of Cancer, 2002, 99, 474-479.	2.3	69
64	Suppression of Melanoma Growth and Metastasis by DNA Vaccination Using an Ultrasound-Responsive and Mannose-Modified Gene Carrier. Molecular Pharmaceutics, 2011, 8, 543-554.	2.3	68
65	Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran conjugate with anionic charge. II. Disposition and pharmacokinetics following intravenous and intramuscular administration. International Journal of Pharmaceutics, 1987, 37, 145-154.	2.6	67
66	Enhanced Anti-Inflammation of Inhaled Dexamethasone Palmitate Using Mannosylated Liposomes in an Endotoxin-Induced Lung Inflammation Model. Molecular Pharmacology, 2008, 74, 1183-1192.	1.0	67
67	Pharmacokinetic evaluation of polymeric carriers. Advanced Drug Delivery Reviews, 1996, 21, 135-155.	6.6	65
68	Novel Galactosylated Liposomes for Hepatocyte‣elective Targeting of Lipophilic Drugs. Journal of Pharmaceutical Sciences, 2001, 90, 105-113.	1.6	65
69	Inhibition of metastatic tumor growth by targeted delivery of antioxidant enzymes. Journal of Controlled Release, 2005, 109, 101-107.	4.8	65
70	Cationic charge-dependent hepatic delivery of amidated serum albumin. Journal of Controlled Release, 2005, 102, 583-594.	4.8	64
71	Efficient Gene Transfer into Macrophages and Dendritic Cells by in Vivo Gene Delivery with Mannosylated Lipoplex via the Intraperitoneal Route. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 828-834.	1.3	64
72	Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriers. Journal of Controlled Release, 2002, 80, 283-294.	4.8	63

#	Article	IF	CITATIONS
73	Enhanced hepatocyte-selective in vivo gene expression by stabilized galactosylated liposome/plasmid DNA complex using sodium chloride for complex formation. Molecular Therapy, 2004, 10, 719-729.	3.7	63
74	A new method for assessment of drug disposition in muscle: Application of statistical moment theory to local perfusion systems. Journal of Pharmacokinetics and Pharmacodynamics, 1985, 13, 609-631.	0.6	62
75	Mannosylated semiconductor quantum dots for the labeling of macrophages. Journal of Controlled Release, 2008, 125, 131-136.	4.8	62
76	Glycosylation-mediated targeting of carriers. Journal of Controlled Release, 2014, 190, 542-555.	4.8	62
77	Regeneration characteristics of mitomycin C-dextran conjugate in relation to its activity Chemical and Pharmaceutical Bulletin, 1983, 31, 2055-2063.	0.6	61
78	Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. International Journal of Pharmaceutics, 2007, 329, 192-198.	2.6	61
79	Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharmaceutical Research, 1996, 13, 599-603.	1.7	60
80	Disposition characteristics of emulsions and incorporated drugs after systemic or local injection. Advanced Drug Delivery Reviews, 2000, 45, 77-88.	6.6	60
81	Inhibition of experimental hepatic metastasis by targeted delivery of catalase in mice. Clinical and Experimental Metastasis, 2004, 21, 213-221.	1.7	59
82	Enhanced Transfection Efficiency into Macrophages and Dendritic Cells by a Combination Method Using Mannosylated Lipoplexes and Bubble Liposomes with Ultrasound Exposure. Human Gene Therapy, 2010, 21, 65-74.	1.4	59
83	Distribution of Silver Nanoparticles to Breast Milk and Their Biological Effects on Breast-Fed Offspring Mice. ACS Nano, 2016, 10, 8180-8191.	7.3	59
84	Prediction of Caco-2 cell permeability using a combination of MO-calculation and neural network. International Journal of Pharmaceutics, 2002, 237, 95-105.	2.6	58
85	Pharmacokinetic Analysis of in Vivo Disposition of Succinylated Proteins Targeted to Liver Nonparenchymal Cells via Scavenger Receptors: Importance of Molecular Size and Negative Charge Density for in Vivo Recognition by Receptors. Journal of Pharmacology and Experimental Therapeutics, 2002. 301. 467-477.	1.3	57
86	Targeting efficiency of galactosylated liposomes to hepatocytes in vivo: effect of lipid composition. Pharmaceutical Research, 2002, 19, 1808-1814.	1.7	56
87	Enhanced DNA vaccine potency by mannosylated lipoplex after intraperitoneal administration. Journal of Gene Medicine, 2006, 8, 824-834.	1.4	56
88	Soluble macromolecular carriers for the delivery of antitumour drugs. Advanced Drug Delivery Reviews, 1989, 3, 247-266.	6.6	55
89	Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting. Journal of Controlled Release, 2000, 69, 369-377.	4.8	55
90	Prediction of Human Skin Permeability Using a Combination of Molecular Orbital Calculations and Artificial Neural Network Biological and Pharmaceutical Bulletin, 2002, 25, 361-366.	0.6	55

#	Article	IF	CITATIONS
91	Anionic Amino Acid Dendrimerâ^'Trastuzumab Conjugates for Specific Internalization in HER2-Positive Cancer Cells. Molecular Pharmaceutics, 2010, 7, 1318-1327.	2.3	55
92	Glycosylated Cationic Liposomes for Cell-Selective Gene Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 171-190.	1.2	55
93	Targeted and sustained drug delivery using PEGylated galactosylated liposomes. International Journal of Pharmaceutics, 2003, 266, 77-84.	2.6	54
94	Intratracheally instilled mannosylated cationic liposome/NFκB decoy complexes for effective prevention of LPS-induced lung inflammation. Journal of Controlled Release, 2011, 149, 42-50.	4.8	54
95	Analysis of Skin Penetration Enhancement Based on a Two-Layer Skin Diffusion Model with Polar and Nonpolar Routes in the Stratum Corneum: Dose-Dependent Effect of 1-Geranylazacycloheptan-2-one on Drugs with Different Lipophilicities Biological and Pharmaceutical Bulletin, 1993, 16, 690-697.	0.6	53
96	Development of Targeted Delivery Systems for Nucleic Acid Drugs. Journal of Drug Targeting, 1997, 4, 337-357.	2.1	53
97	Polyamidoamine dendrimer-conjugated quantum dots for efficient labeling of primary cultured mesenchymal stem cells. Biomaterials, 2011, 32, 6676-6682.	5.7	53
98	Development of a biochip with serially connected pneumatic balloons for cell-stretching culture. Sensors and Actuators B: Chemical, 2011, 156, 486-493.	4.0	53
99	Characterization of plasmid DNA binding and uptake by peritoneal macrophages from class A scavenger receptor knockout mice. Pharmaceutical Research, 1999, 16, 503-508.	1.7	52
100	Quantitative structure/property relationship analysis of Cacoâ€2 permeability using a genetic algorithmâ€based partial least squares method. Journal of Pharmaceutical Sciences, 2002, 91, 2230-2239.	1.6	52
101	PEGylated catalase prevents metastatic tumor growth aggravated by tumor removal. Free Radical Biology and Medicine, 2006, 41, 1449-1458.	1.3	52
102	Pharmacokinetics and <i>In Vivo</i> Gene Transfer of Plasmid DNA Complexed with Mannosylated Poly(L-Lysine) in Mice. Journal of Drug Targeting, 2000, 8, 29-38.	2.1	51
103	Development of Polyethylene Glycol-Conjugated Poly-S-Nitrosated Serum Albumin, a Novel S-Nitrosothiol for Prolonged Delivery of Nitric Oxide in the Blood Circulation in Vivo. Journal of Pharmacology and Experimental Therapeutics, 2005, 314, 1117-1124.	1.3	51
104	Development and pharmacokinetics of galactosylated poly-L-glutamic acid as a biodegradable carrier for liver-specific drug delivery. Pharmaceutical Research, 1996, 13, 880-884.	1.7	50
105	Control of pharmacokinetic profiles of drug—macromolecule conjugates. Advanced Drug Delivery Reviews, 1996, 19, 377-399.	6.6	49
106	Therapeutic effect of intravenous delivery of lipoplexes containing the interferon-β gene and poly I: poly C in a murine lung metastasis model. Cancer Gene Therapy, 2003, 10, 661-668.	2.2	49
107	Pharmacokinetic characteristics and therapeutic effects of mitomycin C-dextran conjugates after intratumoural injection. Journal of Controlled Release, 1998, 52, 239-252.	4.8	48
108	Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. Journal of Controlled Release, 2006, 110, 514-521.	4.8	48

#	Article	IF	CITATIONS
109	Microfluidic devices for construction of contractile skeletal muscle microtissues. Journal of Bioscience and Bioengineering, 2015, 119, 212-216.	1.1	48
110	Tumor growth suppression by the combination of nanobubbles and ultrasound. Cancer Science, 2016, 107, 217-223.	1.7	48
111	Targeted delivery of superoxide dismutase to macrophages via mannose receptor-mediated mechanism. Biochemical Pharmacology, 1994, 47, 853-858.	2.0	47
112	Controlled Biodistribution of Highly Lipophilic Drugs with Various Parenteral Formulations. Journal of Drug Targeting, 1993, 1, 117-124.	2.1	46
113	Control of <i>In Vivo</i> Fate of Albumin Derivatives Utilizing Combined Chemical Modification. Journal of Drug Targeting, 1994, 2, 157-165.	2.1	45
114	Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis. Journal of Controlled Release, 1997, 46, 129-137.	4.8	45
115	Design of polymeric prodrugs of prostaglandin E1 having galactose residue for hepatocyte targeting. Journal of Controlled Release, 1999, 62, 253-262.	4.8	45
116	Preparation and properties of the immunoconjugate composed of anti-human colon cancer monoclonal antibody and mitomycin C-dextran conjugate. Bioconjugate Chemistry, 1992, 3, 132-137.	1.8	44
117	Inhibition of peritoneal dissemination of tumor cells by single dosing of phosphodiester CpG oligonucleotide/cationic liposome complex. Journal of Controlled Release, 2006, 115, 226-233.	4.8	44
118	Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified at Terminal Linkages in Mice. Antisense Research and Development, 1995, 5, 115-121.	3.3	43
119	Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. International Journal of Pharmaceutics, 2004, 287, 147-154.	2.6	43
120	The potential role of fucosylated cationic liposome/NFκB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials, 2007, 28, 532-539.	5.7	43
121	Optimization of tumor-selective targeting by basic fibroblast growth factor-binding peptide grafted PEGylated liposomes. Journal of Controlled Release, 2007, 119, 262-270.	4.8	43
122	Enhanced Gene Transfection in Macrophages Using Mannosylated Cationic Liposome-Polyethylenimine-Plasmid DNA Complexes. Journal of Drug Targeting, 2001, 9, 201-207.	2.1	42
123	QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharmaceutical Research, 2003, 20, 1401-1408.	1.7	42
124	Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors. Biological and Pharmaceutical Bulletin, 2007, 30, 2365-2370.	0.6	42
125	Development of Nitric Oxide Donors for the Treatment of Cardiovascular Diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2007, 5, 204-208.	0.4	42
126	Development of lysine–histidine dendron modified chitosan for improving transfection efficiency in HEK293 cells. Journal of Controlled Release, 2011, 156, 195-202.	4.8	42

#	Article	IF	CITATIONS
127	Analysis of drug penetration through the skin by the two-layer skin model. Pharmaceutical Research, 1989, 06, 931-937.	1.7	41
128	Intracellular drug delivery by genetically engineered high-density lipoprotein nanoparticles. Nanomedicine, 2010, 5, 867-879.	1.7	41
129	Self-assemble gene delivery system for molecular targeting using nucleic acid aptamer. Gene, 2012, 491, 205-209.	1.0	41
130	Efficient suppression of murine intracellular adhesion molecule-1 using ultrasound-responsive and mannose-modified lipoplexes inhibits acute hepatic inflammation. Hepatology, 2012, 56, 259-269.	3.6	41
131	Biodistribution characteristics of all-trans retinoic acid incorporated in liposomes and polymeric micelles following intravenous administration. Journal of Pharmaceutical Sciences, 2005, 94, 2606-2615.	1.6	40
132	Inhibition of tumour metastasis by targeted delivery of antioxidant enzymes. Expert Opinion on Drug Delivery, 2006, 3, 355-369.	2.4	40
133	Design for cell-specific targeting of proteins utilizing sugar-recognition mechanism: effect of molecular weight of proteins on targeting efficiency. Pharmaceutical Research, 1995, 12, 209-214.	1.7	39
134	Encapsulation of the synthetic retinoids Am80 and LE540 into polymeric micelles and the retinoids' release control. Journal of Controlled Release, 2009, 136, 187-195.	4.8	39
135	<i>In Vitro</i> Evaluation of Inhibitory Effect of Nuclear Factor-KappaB Activity by Small Interfering RNA on Pro-tumor Characteristics of M2-Like Macrophages. Biological and Pharmaceutical Bulletin, 2014, 37, 137-144.	0.6	39
136	Analysis of hepatic disposition of galactosylated cationic liposome/plasmid DNA complexes in perfused rat liver. Pharmaceutical Research, 2003, 20, 1452-1459.	1.7	38
137	Tissue-Specific Characteristics of in Vivo Electric Gene: Transfer by Tissue and Intravenous Injection of Plasmid DNA. Pharmaceutical Research, 2005, 22, 883-891.	1.7	38
138	Liver targeting of catalase by cationization for prevention of acute liver failure in mice. Journal of Controlled Release, 2006, 110, 273-282.	4.8	38
139	Renal press-mediated transfection method for plasmid DNA and siRNA to the kidney. Biochemical and Biophysical Research Communications, 2008, 372, 383-387.	1.0	38
140	Renal Disposition Characteristics of Oligonucleotides Modified at Terminal Linkages in the Perfused Rat Kidney. Antisense Research and Development, 1995, 5, 279-287.	3.3	37
141	Use of lipoplex-induced nuclear factor-κB activation to enhance transgene expression by lipoplex in mouse lung. Journal of Gene Medicine, 2006, 8, 53-62.	1.4	36
142	Evaluation of the potential of doxorubicin loaded microbubbles as a theranostic modality using a murine tumor model. Acta Biomaterialia, 2015, 19, 112-118.	4.1	36
143	Pharmacokinetic Evaluation of Mannosylated Bovine Serum Albumin as a Liver Cell-Specific Carrier: Quantitative Comparison with Other Hepatotropic Ligands. Journal of Drug Targeting, 1999, 6, 349-360.	2.1	35
144	In vivo recognition of mannosylated proteins by hepatic mannose receptors and mannan-binding protein. American Journal of Physiology - Renal Physiology, 2001, 280, G879-G889.	1.6	35

#	Article	IF	CITATIONS
145	Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes. Journal of Controlled Release, 2006, 116, 58-63.	4.8	35
146	Neutralized Nanoparticle Composed of SSâ€Cleavable and pHâ€Activated Lipidâ€Like Material as a Longâ€Lasting and Liverâ€Specific Gene Delivery System. Advanced Healthcare Materials, 2014, 3, 1222-1229.	⁵ 3.9	35
147	Statistical moment analysis of hepatobiliary transport of phenol red in the perfused rat liver. Pharmaceutical Research, 1989, 06, 140-146.	1.7	34
148	Hepatocyte-specific distribution of catalase and its inhibitory effect on hepatic ischemia/reperfusion injury in mice. Free Radical Research, 1999, 30, 265-274.	1.5	34
149	Theoretical considerations involving the pharmacokinetics of plasmid DNA. Advanced Drug Delivery Reviews, 2005, 57, 675-688.	6.6	34
150	Intravenous administration of mannosylated cationic liposome/NFκB decoy complexes effectively prevent LPS-induced cytokine production in a murine liver failure model. FEBS Letters, 2006, 580, 3706-3714.	1.3	34
151	High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases. Journal of Controlled Release, 2017, 266, 301-309.	4.8	34
152	Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. Journal of Drug Targeting, 2006, 14, 536-545.	2.1	33
153	Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice. Cancer Letters, 2010, 287, 75-81.	3.2	33
154	Development of Novel Drug and Gene Delivery Carriers Composed ofÂSingle-Walled Carbon Nanotubes and Designed Peptides With PEGylation. Journal of Pharmaceutical Sciences, 2016, 105, 2815-2824.	1.6	33
155	Pharmacokinetics in design of polymeric drug delivery systems. Journal of Controlled Release, 1994, 31, 163-171.	4.8	32
156	Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System. Oligonucleotides, 1996, 6, 177-183.	4.4	32
157	Important role of serum proteins associated on the surface of particles in their hepatic disposition. Journal of Controlled Release, 2002, 83, 89-96.	4.8	32
158	Exclusive Photothermal Heat Generation by a Gadolinium Bis(naphthalocyanine) Complex and Inclusion into Modified High-Density Lipoprotein Nanocarriers for Therapeutic Applications. ACS Nano, 2013, 7, 8908-8916.	7.3	32
159	Role of pharmacokinetic consideration for the development of drug delivery systems: A historical overview. Advanced Drug Delivery Reviews, 2020, 157, 71-82.	6.6	32
160	Inhibition of liver metastasis by all-trans retinoic acid incorporated into O/W emulsions in mice. International Journal of Pharmaceutics, 2006, 321, 42-49.	2.6	31
161	SOD derivatives prevent metastatic tumor growth aggravated by tumor removal. Clinical and Experimental Metastasis, 2008, 25, 531-536.	1.7	31
162	Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. Journal of Controlled Release, 2010, 145, 9-16.	4.8	31

#	Article	IF	CITATIONS
163	Mechanisms of hepatic disposition of polystyrene microspheres in rats: Effects of serum depend on the sizes of microspheres. Journal of Controlled Release, 1999, 61, 241-250.	4.8	30
164	Enhanced gene expression in lung by a stabilized lipoplex using sodium chloride for complex formation. Journal of Gene Medicine, 2005, 7, 1526-1533.	1.4	30
165	Effect of the Particle Size of Galactosylated Lipoplex on Hepatocyte-Selective Gene Transfection after Intraportal Administration. Biological and Pharmaceutical Bulletin, 2006, 29, 1521-1523.	0.6	30
166	Novel Hierarchical Classification and Visualization Method for Multiobjective Optimization of Drug Properties:  Application to Structureâ^'Activity Relationship Analysis of Cytochrome P450 Metabolism. Journal of Chemical Information and Modeling, 2008, 48, 364-369.	2.5	30
167	Prevention of Hepatic Ischemia/Reperfusion Injury by Prolonged Delivery of Nitric Oxide to the Circulating Blood in Mice. Transplantation, 2008, 85, 264-269.	0.5	30
168	Prevention of ischemia/reperfusion injury by hepatic targeting of nitric oxide in mice. Journal of Controlled Release, 2009, 140, 12-17.	4.8	30
169	Evaluation of proinflammatory cytokine production and liver injury induced by plasmid DNA/cationic liposome complexes with various mixing ratios in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 303-309.	2.0	30
170	The elucidation of gene transferring mechanism by ultrasound-responsive unmodified and mannose-modified lipoplexes. Biomaterials, 2011, 32, 4659-4669.	5.7	30
171	Improvement of Therapeutic Effect of Human Recombinant Superoxide Dismutase on Ischemic Acute Renal Failure in the Rat via Cationization and Conjugation with Polyethylene Glycol. Journal of Drug Targeting, 1994, 2, 317-321.	2.1	29
172	Interaction with Blood Components Plays a Crucial Role in Asialoglycoprotein Receptor-Mediated in Vivo Gene Transfer by Galactosylated Lipoplex. Journal of Pharmacology and Experimental Therapeutics, 2005, 315, 484-493.	1.3	29
173	Pharmacokinetic Analysis of Lectin-dependent Biodistribution of Fucosylated Bovine Serum Albumin: A Possible Carrier for Kupffer Cells. Journal of Drug Targeting, 2001, 9, 341-351.	2.1	28
174	Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells. International Journal of Pharmaceutics, 2005, 301, 255-261.	2.6	28
175	Self-assembling lipid modified glycol-split heparin nanoparticles suppress lipopolysaccharide-induced inflammation through TLR4–NF-κB signaling. Journal of Controlled Release, 2014, 194, 332-340.	4.8	28
176	Biodistribution Characteristics of Galactosylated Emulsions and Incorporated Probucol for Hepatocyte-Selective Targeting of Lipophilic Drugs in Mice. Pharmaceutical Research, 2004, 21, 932-939.	1.7	27
177	Inhibition of adhesion and proliferation of peritoneally disseminated tumor cells by pegylated catalase. Clinical and Experimental Metastasis, 2006, 23, 269-278.	1.7	27
178	Prevention of pulmonary metastasis from subcutaneous tumors by binary system-based sustained delivery of catalase. Journal of Controlled Release, 2009, 137, 110-115.	4.8	27
179	Enhanced in vivo antitumor efficacy of fenretinide encapsulated in polymeric micelles. International Journal of Pharmaceutics, 2009, 373, 100-106.	2.6	27
180	Suppression of experimental arthritis with self-assembling glycol-split heparin nanoparticles via inhibition of TLR4–NF-κB signaling. Journal of Controlled Release, 2014, 194, 295-300.	4.8	27

#	Article	IF	CITATIONS
181	Enhancement of the anti-tumor effect of DNA vaccination using an ultrasound-responsive mannose-modified gene carrier in combination with doxorubicin-encapsulated PEGylated liposomes. International Journal of Pharmaceutics, 2014, 475, 401-407.	2.6	27
182	Tumor Localization andin vivoAntitumor Activity of the Immunoconjugate Composed of Anti-human Colon Cancer Monoclonal Antibody and Mitomycin C-Dextran Conjugate. Japanese Journal of Cancer Research, 1991, 82, 219-226.	1.7	26
183	Disposition characteristics of protein drugs in the perfused rat kidney. Pharmaceutical Research, 1993, 10, 823-827.	1.7	26
184	Manipulation of Renal Disposition of Human Recombinant Superoxide Dismutase by Chemical Modification Biological and Pharmaceutical Bulletin, 1994, 17, 296-301.	0.6	26
185	Tissue and intrahepatic distribution and subcellular localization of a mannosylated lipoplex after intravenous administration in mice. Journal of Controlled Release, 2004, 98, 157-167.	4.8	26
186	Hydrogen peroxideâ€mediated nuclear factor κB activation in both liver and tumor cells during initial stages of hepatic metastasis. Cancer Science, 2008, 99, 1546-1552.	1.7	26
187	Key Physiological Phenomena Governing Transgene Expression Based on Tissue Pressure-Mediated Transfection in Mice. Biological and Pharmaceutical Bulletin, 2010, 33, 1627-1632.	0.6	26
188	In vivo Site-Specific Transfection of Naked Plasmid DNA and siRNAs in Mice by Using a Tissue Suction Device. PLoS ONE, 2012, 7, e41319.	1.1	26
189	Hepatic targeting of drugs and proteins by chemical modification. Journal of Controlled Release, 1995, 36, 99-107.	4.8	25
190	Mannosylated Superoxide Dismutase Inhibits Hepatic Reperfusion Injury in Rats. Journal of Surgical Research, 1996, 60, 36-40.	0.8	25
191	Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice. Journal of Drug Targeting, 2005, 13, 479-487.	2.1	25
192	Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. Journal of Controlled Release, 2010, 141, 252-259.	4.8	25
193	Development of anionic bubble lipopolyplexes for efficient and safe gene transfection with ultrasound exposure in mice. Journal of Controlled Release, 2014, 176, 24-34.	4.8	25
194	The development of mechanically formed stable nanobubbles intended for sonoporation-mediated gene transfection. Drug Delivery, 2017, 24, 320-327.	2.5	25
195	Disposition of radioactivity after injection of liver-targeted proteins labeled with 1111n or 1251. Effect of labeling on distribution and excretion of radioactivity in rats. Journal of Pharmaceutical Sciences, 1999 88 577-585. Synthesis and pharmacological activity of a novel water-soluble hepatocyte-specific polymeric	1.6	24
196	prodrug of prostaglandin E 1 using lactosylated poly(I -glutamic hydrazide) as a carrier 1 1Abbreviations: PGE1, prostaglandin E1; PLGA-HZ, poly(I-glutamic hydrazide); Lac-NH-PLGA, lactosylated poly(I-glutamic hydrazide); PGE1 conjugate, prostaglandin E1 prodrug using Lac-NH-PLGA as a carrier; DTPA anhydride, diethylenetriamine-N,N,N′,N″,Pentaacetic dianhydride; GPT, glutamic pyruvic	2.0	24
197	transaminase; AUC, area und. Biochemical Pharmacology, 2001, 62, 1531-1536. Artificial neural network analysis for predicting human percutaneous absorption taking account of vehicle properties. Journal of Toxicological Sciences, 2015, 40, 277-294.	0.7	24
198	Disposition Characteristics of Glycosylated Poly(amino acids) as Liver Cell-Specific Drug Carrier. Journal of Drug Targeting, 1998, 6, 229-239.	2.1	23

#	Article	IF	CITATIONS
199	Targeted Delivery of Prostaglandin E ₁ to Hepatocytes Using Galactosylated Liposomes. Journal of Drug Targeting, 2000, 8, 137-142.	2.1	23
200	Pharmacokinetics and preventive effects of targeted catalase derivatives on hydrogen peroxide-induced injury in perfused rat liver. Pharmaceutical Research, 2002, 19, 1815-1821.	1.7	23
201	Use of mannosylated cationic liposomes/ immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. Journal of Gene Medicine, 2008, 10, 392-399.	1.4	23
202	Improvement of Insulin Resistance by Removal of Systemic Hydrogen Peroxide by PEGylated Catalase in Obese Mice. Molecular Pharmaceutics, 2010, 7, 2069-2076.	2.3	23
203	Mesoscopic Metal Nanoparticles Doubly Functionalized with Natural and Engineered Lipidic Dispersants for Therapeutics. ACS Nano, 2014, 8, 7370-7376.	7.3	23
204	Development of PEGylated Cysteine-Modified Lysine Dendrimers with Multiple Reduced Thiols To Prevent Hepatic Ischemia/Reperfusion Injury. Molecular Pharmaceutics, 2016, 13, 2867-2873.	2.3	23
205	Synthesis and Functional Characterization of Novel Sialyl LewisX Mimic-Decorated Liposomes for E-selectin-Mediated Targeting to Inflamed Endothelial Cells. Molecular Pharmaceutics, 2017, 14, 1528-1537.	2.3	23
206	Pharmacokinetic analysis of drug absorption from muscle based on a physiological diffusion model: effect of molecular size on absorption. Pharmaceutical Research, 1992, 09, 161-168.	1.7	22
207	Involvement of activated transcriptional process in efficient gene transfection using unmodified and mannose-modified bubble lipoplexes with ultrasound exposure. Journal of Controlled Release, 2011, 156, 355-363.	4.8	22
208	Preparation of immunostimulatory single-walled carbon nanotube/CpG DNA complexes and evaluation of their potential in cancer immunotherapy. International Journal of Pharmaceutics, 2014, 471, 214-223.	2.6	22
209	Anti-MUC1 Aptamer/Negatively Charged Amino Acid Dendrimer Conjugates for Targeted Delivery to Human Lung Adenocarcinoma A549 Cells. Biological and Pharmaceutical Bulletin, 2016, 39, 1734-1738.	0.6	22
210	Control of Plasma Cholesterol-Lowering Action of Probucol with Various Lipid Carrier Systems Biological and Pharmaceutical Bulletin, 1998, 21, 492-497.	0.6	21
211	Modeling and Prediction of Solvent Effect on Human Skin Permeability using Support Vector Regression and Random Forest. Pharmaceutical Research, 2015, 32, 3604-3617.	1.7	21
212	Development of fluorous lipid-based nanobubbles for efficiently containing perfluoropropane. International Journal of Pharmaceutics, 2015, 487, 64-71.	2.6	21
213	Analysis of In Vivo Nuclear Factor-ήB Activation during Liver Inflammation in Mice: Prevention by Catalase Delivery. Molecular Pharmacology, 2007, 71, 446-453.	1.0	20
214	Inhibition of peritoneal dissemination of tumor cells by cationized catalase in mice. Journal of Controlled Release, 2007, 119, 121-127.	4.8	20
215	Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. Journal of Controlled Release, 2007, 119, 271-278.	4.8	20
216	Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in mice. Journal of Controlled Release, 2008, 126, 274-280.	4.8	20

#	Article	IF	CITATIONS
217	Pressure-Mediated Transfection of Murine Spleen and Liver. Human Gene Therapy, 2009, 20, 1157-1167.	1.4	20
218	Enhanced Gene Transfection in Macrophages by Histidine-Conjugated Mannosylated Cationic Liposomes. Biological and Pharmaceutical Bulletin, 2009, 32, 1628-1631.	0.6	20
219	In vivo evaluation of acyclovir prodrug penetration and metabolism through rat skin using a diffusion/bioconversion model. Pharmaceutical Research, 1997, 14, 56-62.	1.7	19
220	Pharmacokinetic considerations regarding non-viral cancer gene therapy. Cancer Science, 2008, 99, 856-862.	1.7	19
221	Systematic Research of Peptide Spacers Controlling Drug Release from Macromolecular Prodrug System, Carboxymethyldextran Polyalcoholâ^'Peptideâ^'Drug Conjugates. Bioconjugate Chemistry, 2009, 20, 60-70.	1.8	19
222	Pivotal role of oxidative stress in tumor metastasis under diabetic conditions in mice. Journal of Controlled Release, 2013, 170, 191-197.	4.8	19
223	Disposition Characteristics of Model Macromolecules in the Perfused Rat Kidney Biological and Pharmaceutical Bulletin, 1993, 16, 158-162.	0.6	18
224	Theoretical design of prodrug-enhancer combination based on a skin diffusion model: prediction of permeation of acyclovir prodrugs treated with 1-geranylazacycloheptan-2-one. Pharmaceutical Research, 1996, 13, 427-432.	1.7	18
225	Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation. Biochimica Et Biophysica Acta - General Subjects, 1999, 1427, 183-192.	1.1	18
226	Physicochemical, tissue distribution, and vasodilation characteristics of nitrosated serum albumin: delivery of nitric oxide in vivo. Journal of Pharmaceutical Sciences, 2004, 93, 2343-2352.	1.6	18
227	Two―and threeâ€dimensional QSAR of carrierâ€mediated transport of βâ€lactam antibiotics in Cacoâ€2 cells. Journal of Pharmaceutical Sciences, 2004, 93, 3057-3065.	1.6	18
228	Visualization of Large-Scale Aqueous Solubility Data Using a Novel Hierarchical Data Visualization Technique. Journal of Chemical Information and Modeling, 2006, 46, 1054-1059.	2.5	18
229	Tumour-associated macrophages targeted transfection with NF-κB decoy/mannose-modified bubble lipoplexes inhibits tumour growth in tumour-bearing mice. Journal of Drug Targeting, 2014, 22, 439-449.	2.1	18
230	Automated Information Extraction and Structureâ^'Activity Relationship Analysis of Cytochrome P450 Substrates. Journal of Chemical Information and Modeling, 2011, 51, 378-385.	2.5	17
231	Cationized catalase-loaded hydrogel for growth inhibition of peritoneally disseminated tumor cells. Journal of Controlled Release, 2007, 122, 151-158.	4.8	16
232	Anti-tumor Effect of All-Trans Retinoic Acid Loaded Polymeric Micelles in Solid Tumor Bearing Mice. Pharmaceutical Research, 2008, 25, 428-434.	1.7	16
233	Immunostimulatory Characteristics Induced by Linear Polyethyleneimine–Plasmid DNA Complexes in Cultured Macrophages. Human Gene Therapy, 2009, 20, 137-145.	1.4	16
234	Size control of lipid-based drug carrier by drug loading. Molecular BioSystems, 2010, 6, 789.	2.9	16

#	Article	IF	CITATIONS
235	Development of a Novel Composite Material with Carbon Nanotubes Assisted by Self-Assembled Peptides Designed in Conjunction with Î ² -Sheet Formation. Journal of Pharmaceutical Sciences, 2012, 101, 3398-3412.	1.6	16
236	Kidney-selective gene transfection using anionic bubble lipopolyplexes with renal ultrasound irradiation in mice. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1829-1838.	1.7	16
237	Hexaphyrin as a Potential Theranostic Dye for Photothermal Therapy and ¹⁹ F Magnetic Resonance Imaging. ChemBioChem, 2017, 18, 951-959.	1.3	16
238	Development of a DNA Vaccine for Melanoma Metastasis by Inhalation Based on an Analysis of Transgene Expression Characteristics of Naked pDNA and a Ternary Complex in Mouse Lung Tissues. Pharmaceutics, 2020, 12, 540.	2.0	16
239	Hepatic disposition characteristics of 111In-labeled lactosaminated bovine serum albumin in rats. Pharmaceutical Research, 1991, 08, 1253-1257.	1.7	15
240	Pharmacokinetic analysis of uptake process of lactosaminated albumin in rat liver constant infusion experiments. International Journal of Pharmaceutics, 1992, 80, 101-108.	2.6	15
241	Improved anti-oxidant activity of superoxide dismutase by direct chemical modification. Journal of Controlled Release, 2006, 111, 204-211.	4.8	15
242	Evaluation of Osteoclastogenesis via NFκB Decoy/mannosylated Cationic Liposome-Mediated Inhibition of Pro-inflammatory Cytokine Production from Primary Cultured Macrophages. Pharmaceutical Research, 2011, 28, 742-751.	1.7	15
243	Antitumor effect of nuclear factorâ€̂PB decoy transfer by mannoseâ€modified bubble lipoplex into macrophages in mouse malignant ascites. Cancer Science, 2014, 105, 1049-1055.	1.7	15
244	Inhibition of Cancer Cell Growth by GRP78 siRNA Lipoplex <i>via</i> Activation of Unfolded Protein Response. Biological and Pharmaceutical Bulletin, 2014, 37, 648-653.	0.6	15
245	Skin Penetration Enhancement of Acyclovir by Prodrug-Enhancer Combination Biological and Pharmaceutical Bulletin, 1994, 17, 1141-1143.	0.6	14
246	Pharmacokinetic Evaluation of Biodistribution Data Obtained with Radiolabeled Proteins in Mice Biological and Pharmaceutical Bulletin, 1999, 22, 214-218.	0.6	14
247	NFκB decoy delivery using dendritic poly(l-lysine) for treatment of endotoxin-induced hepatitis in mice. Bioorganic and Medicinal Chemistry, 2009, 17, 4990-4995.	1.4	14
248	Glycosylated carriers for cell-selective and nuclear delivery of nucleic acids. Frontiers in Bioscience - Landmark, 2011, 16, 2970.	3.0	14
249	Automated Extraction of Information from the Literature on Chemical-CYP3A4 Interactions. Journal of Chemical Information and Modeling, 2007, 47, 2449-2455.	2.5	13
250	Mannosylated Cationic Liposomes/CpG DNA Complex for the Treatment of Hepatic Metastasis after Intravenous Administration in Mice. Journal of Pharmaceutical Sciences, 2009, 98, 1193-1197.	1.6	13
251	Synthesis and evaluation of glyco-coated liposomes as drug carriers for active targeting in drug delivery systems. Carbohydrate Research, 2015, 405, 78-86.	1.1	13
252	Development of a Support Vector Machine-Based System to Predict Whether a Compound Is a Substrate of a Given Drug Transporter Using Its Chemical Structure. Journal of Pharmaceutical Sciences, 2016, 105, 2222-2230.	1.6	13

#	Article	IF	CITATIONS
253	Quantitative prediction of ionization effect on human skin permeability. International Journal of Pharmaceutics, 2017, 522, 222-233.	2.6	13
254	Urokinase injection-triggered clearance enhancement of a 4-arm PEG-conjugated 64Cu-bombesin analog tetramer: A novel approach for the improvement of PET imaging contrast. International Journal of Pharmaceutics, 2018, 545, 206-214.	2.6	13
255	Pharmacokinetic analysis of scavenger receptor-mediated uptake of anionized proteins in the isolated perfused rat liver. International Journal of Pharmaceutics, 1997, 151, 15-26.	2.6	12
256	Block copolymer design for stable encapsulation of N-(4-hydroxyphenyl)retinamide into polymeric micelles in mice. International Journal of Pharmaceutics, 2008, 357, 318-322.	2.6	12
257	Analysis of Hepatic Disposition of Native and Galactosylated Polyethylenimine Complexed with Plasmid DNA in Perfused Rat Liver. Drug Metabolism and Pharmacokinetics, 2003, 18, 230-237.	1.1	11
258	Intracellular distribution of NFκB decoy and its inhibitory effect on TNFα production by LPS stimulated RAW 264.7 cells. Journal of Controlled Release, 2005, 107, 373-382.	4.8	11
259	Quantitative structure/activity relationship modelling of pharmacokinetic properties using genetic algorithm-combined partial least squares method. Journal of Drug Targeting, 2006, 14, 496-504.	2.1	11
260	Intracellular Trafficking Is the Important Process That Determines the Optimal Charge Ratio on Transfection by Galactosylated Lipoplex in HepG2 Cells. Biological and Pharmaceutical Bulletin, 2006, 29, 1986-1990.	0.6	11
261	Suppressive effects of sugar-modified cationic liposome/NF-κB decoy complexes on adenovirus vector-induced innate immune responses. Journal of Controlled Release, 2009, 133, 139-145.	4.8	11
262	Development of Bone-Targeted Catalase Derivatives for Inhibition of Bone Metastasis of Tumor Cells in Mice. Journal of Pharmaceutical Sciences, 2012, 101, 552-557.	1.6	11
263	The involvement of NK cell activation following intranasal administration of CpG DNA lipoplex in the prevention of pulmonary metastasis and peritoneal dissemination in mice. Clinical and Experimental Metastasis, 2012, 29, 63-70.	1.7	11
264	Factors Influencing the Surface Modification of Mesenchymal Stem Cells with Fluorescein-Pegylated Lipids. Biological and Pharmaceutical Bulletin, 2013, 36, 1731-1738.	0.6	11
265	Development of PEGylated serum albumin with multiple reduced thiols as a long-circulating scavenger of reactive oxygen species for the treatment of fulminant hepatic failure in mice. Free Radical Biology and Medicine, 2014, 69, 318-323.	1.3	11
266	An Evolutionary Search Algorithm for Covariate Models in Population Pharmacokinetic Analysis. Journal of Pharmaceutical Sciences, 2017, 106, 2407-2411.	1.6	11
267	Efficient protection by cationized catalase against H2O2 injury in primary cultured alveolar epithelial cells. Journal of Controlled Release, 2007, 121, 74-80.	4.8	10
268	Development of a suction device for stabilizing in vivo real-time imaging of murine tissues. Journal of Bioscience and Bioengineering, 2011, 112, 508-510.	1.1	10
269	Bovine Serum Albumin as a Lyoprotectant for Preparation of DNA Dry Powder Formulations Using the Spray-Freeze Drying Method. Biological and Pharmaceutical Bulletin, 2012, 35, 1178-1181.	0.6	10
270	Implantable pneumatically actuated microsystem for renal pressure-mediated transfection in mice. Journal of Controlled Release, 2012, 159, 85-91.	4.8	10

#	Article	IF	CITATIONS
271	Advocation and advancements of EPR effect theory in drug delivery science: A commentary. Journal of Controlled Release, 2022, 346, 355-357.	4.8	10
272	Assessment of drug disposition in the perfused rat brain by statistical moment analysis. Pharmaceutical Research, 1991, 08, 683-689.	1.7	9
273	Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by direct cationization. Biochimica Et Biophysica Acta - General Subjects, 1997, 1335, 91-98.	1.1	9
274	Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11). Journal of Controlled Release, 2006, 115, 134-139.	4.8	9
275	Incorporation of all-trans retinoic acid into lipoplexes inhibits nuclear factor $\hat{I}^{e}B$ activation mediated liver injury induced by lipoplexes in mice. Journal of Gene Medicine, 2008, 10, 61-69.	1.4	9
276	Insertion of nuclear factor-κB binding sequence into plasmid DNA for increased transgene expression in colon carcinoma cells. Journal of Biotechnology, 2008, 133, 36-41.	1.9	9
277	Comparison of piggyBac transposition efficiency between linear and circular donor vectors in mammalian cells. Journal of Biotechnology, 2011, 154, 205-208.	1.9	9
278	Computer-based Evolutionary Search for a Nonlinear Conversion Function for Establishing In Vitro-In Vivo Correlation (IVIVC) of Oral Drug Formulations. Drug Metabolism and Pharmacokinetics, 2012, 27, 280-285.	1.1	9
279	Effect of complexation with dextran sulfate on the lymphatic delivery of bleomycin following intrastitial administration Journal of Pharmacobio-dynamics, 1979, 2, 383-390.	0.5	8
280	Renal disposition of recombinant human interleukin-11 in the isolated perfused rat kidney. Pharmaceutical Research, 1997, 14, 86-90.	1.7	8
281	Evaluation of Long-Term Gene Expression in Mouse Liver Using PhiC31 Integrase and Hydrodynamic Injection. Biological and Pharmaceutical Bulletin, 2012, 35, 1182-1186.	0.6	8
282	Anti-inflammatory Effect of Self-assembling Glycol-Split Glycosaminoglycan-Stearylamine Conjugates in Lipopolysaccharide-Stimulated Macrophages. Biological and Pharmaceutical Bulletin, 2017, 40, 540-545.	0.6	8
283	Targeted Gene Delivery: Importance of Administration Routes. , 0, , .		7
284	Binding and structure-kinetic relationship analysis of selective TLR4-targeted immunosuppressive self-assembling heparin nanoparticles. International Journal of Pharmaceutics, 2018, 552, 76-83.	2.6	7
285	Effects of Tissue Pressure on Transgene Expression Characteristics via Renal Local Administration Routes from Ureter or Renal Artery in the Rat Kidney. Pharmaceutics, 2020, 12, 114.	2.0	7
286	Influence of Cholesterol Composition on the Association of Serum Mannan-Binding Proteins with Mannosylated Liposomes. Biological and Pharmaceutical Bulletin, 2006, 29, 613-618.	0.6	6
287	Analysis of the molecular interaction between mannosylated proteins and serum mannan-binding lectins. International Journal of Pharmaceutics, 2006, 316, 117-123.	2.6	6
288	A novel multi-dimensional visualization technique for understanding the design parameters of drug formulations. Computers and Chemical Engineering, 2010, 34, 1306-1311.	2.0	6

#	Article	IF	CITATIONS
289	Liver Suction-Mediated Transfection in Mice Using a Pressure-Controlled Computer System. Biological and Pharmaceutical Bulletin, 2014, 37, 569-575.	0.6	6
290	Optimization of renal transfection using a renal suction-mediated transfection method in mice. Journal of Drug Targeting, 2016, 24, 450-456.	2.1	6
291	Hepatocyte-Selective Gene Transfer by Galactosylated Protein/Linear Polyethyleneimine/Plasmid DNA Complexes in Mice. Journal of Biomedical Nanotechnology, 2007, 3, 277-284.	0.5	6
292	Analysis of the molecular interaction of glycosylated proteins with rabbit liver asialoglycoprotein receptors using surface plasmon resonance spectroscopy. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 966-972.	1.4	5
293	Structure-Activity Relationship Modeling for Predicting Interactions with Pregnane X Receptor by Recursive Partitioning. Drug Metabolism and Pharmacokinetics, 2012, 27, 506-512.	1.1	5
294	Long-termin vivogene expression in mouse kidney usingϕC31 integrase and electroporation. Journal of Drug Targeting, 2015, 23, 427-435.	2.1	5
295	Use of Membrane Potential to Achieve Transmembrane Modification with an Artificial Receptor. Bioconjugate Chemistry, 2017, 28, 296-301.	1.8	5
296	InÂVitro Cellular Gene Delivery Employing a Novel Composite Material of Single-Walled Carbon Nanotubes Associated With Designed Peptides With Pegylation. Journal of Pharmaceutical Sciences, 2017, 106, 792-802.	1.6	5
297	Sialyl LewisX mimic-decorated liposomes for anti-angiogenic everolimus delivery to E-selectin expressing endothelial cells. RSC Advances, 2019, 9, 20518-20527.	1.7	5
298	Statistical moments and disposition parameters in a local perfusion system under mammillary nonequilibrium condition. Journal of Pharmacokinetics and Pharmacodynamics, 1990, 18, 449-458.	0.6	4
299	Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f. Journal of Pharmaceutical and Biomedical Analysis, 2007, 43, 1290-1296.	1.4	4
300	Sustained Release of Mitomycin C from Its Conjugate with Single-Walled Carbon Nanotubes Associated by Pegylated Peptide. Biological and Pharmaceutical Bulletin, 2016, 39, 1687-1693.	0.6	4
301	Evaluation of inflammatory responses due to small interfering RNA transfer using unmodified- and mannose-modified bubble lipoplexes with ultrasound exposure in primary cultured macrophages. Journal of Drug Targeting, 2014, 22, 732-738.	2.1	3
302	Evaluation of the Theranostic Potential of Perfluorohexane-Based Acoustic Nanodroplets. Biological and Pharmaceutical Bulletin, 2019, 42, 2038-2044.	0.6	3
303	Tissue suction-mediated gene transfer to the beating heart in mice. PLoS ONE, 2020, 15, e0228203.	1.1	3
304	Evaluation of transgene expression characteristics and DNA vaccination against melanoma metastasis of an intravenously injected ternary complex with biodegradable dendrigraft poly-L-lysine in mice. Drug Delivery, 2021, 28, 542-549.	2.5	3
305	Role of Tyrosine and Tryptophan in Chemically Modified Serum Albumin on Its Tissue Distribution. Biological and Pharmaceutical Bulletin, 2006, 29, 1926-1930.	0.6	2
306	Automated Extraction of Information on Chemical–P-glycoprotein Interactions from the Literature. Journal of Chemical Information and Modeling, 2013, 53, 2506-2510.	2.5	2

#	Article	IF	CITATIONS
307	Targeted gene integration using the combination of a sequence-specific DNA-binding protein and phiC31 integrase. Journal of Biotechnology, 2014, 186, 139-147.	1.9	2
308	Development of mKO2 fusion proteins for real-time imaging and mechanistic investigation of the degradation kinetics of human llºBα in living cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 2019, 1866, 190-198.	1.9	2
309	Development of cancer immune therapy by cell targeted nucleic acid delivery. Drug Delivery System, 2008, 23, 138-144.	0.0	2
310	Intravital imaging of live mice at cellular resolution. Drug Delivery System, 2016, 31, 146-153.	0.0	1
311	Oligonuleotide Delivery with Dendritic Poly(L-lysine) for Treatments of the Liver Disorders. Materials Research Society Symposia Proceedings, 2009, 1237, 1.	0.1	0
312	Development of in vivo gene delivery methods in mice using tissue suction devices for abdominal endoscopic gene therapy. , 2012, , .		0
313	Real Time Imaging of Biological Phenomena with Super-duper Luminescent Proteins. Cytologia, 2015, 80, 1-2.	0.2	0
314	The Application of the <i>in-Situ</i> Hyperthermia Emission from Acoustic Nanodroplets for Theranostic Dual-Imaging and Antitumor Modalities. Biological and Pharmaceutical Bulletin, 2020, 43, 1141-1145.	0.6	0
315	Strictness and Transparency in Approval Process of Medical Products: Japanese Situation. Clinical Pharmacology and Therapeutics, 2021, 109, 290-290.	2.3	0
316	Gene delivery to the lung. Drug Delivery System, 2008, 23, 454-459.	0.0	0
317	[Opinion]Expectation for regulatory science. Drug Delivery System, 2014, 29, 188-188.	0.0	0